Immunomodulators (IL-4/IL-13 pathway biologics)
- Block type-2 IL-4/IL-13 signaling
- Dupilumab is the prototype
- Uses: atopic dermatitis, asthma, CRSwNP
- Conjunctivitis can occur
- Not broadly immunosuppressive like many biologics
- Steroid-sparing efficacy can be substantial
Class at a glance
- Block type-2 IL-4/IL-13 signaling
Practical pearls
- Dupilumab is the prototype
Clinical role
- Uses: atopic dermatitis, asthma, CRSwNP
- Conjunctivitis can occur
Other practical pearls
- Not broadly immunosuppressive like many biologics
- Steroid-sparing efficacy can be substantial
Pearls
- Conjunctivitis/keratitis shared by dupilumab, lebrikizumab, tralokinumab
- Dupilumab: facial/neck redness; may provoke psoriasis
- Eosinophilia and herpes zoster reported
Self-check
- What are the main clinical uses of Immunomodulators (IL-4/IL-13 pathway biologics)?
Atopic dermatitis, asthma, CRSwNP. - What ocular adverse effect can occur with IL-4/IL-13 pathway biologics?
Conjunctivitis.
Drugs in this class (3)
All drug classes · Open Immunomodulators (IL-4/IL-13 pathway biologics) in the interactive console ↗